Analyst firms · H.C. Wainwright · SRPT
H.C. Wainwright SRPT price target and rating history
Sarepta Therapeutics Inc. (SRPT) · Health Care
H.C. Wainwright rates Sarepta Therapeutics Inc. (SRPT) Sell with a $5 price target, as of its latest action on Jul 29, 2025. It has published 4 rating actions on SRPT since November 2024, including 1 upgrade and 1 downgrade. Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50.
- Current rating
- Sell
- Price target
- $5
- Median target, all firms
- $23.50
- Actions on SRPT
- 4
H.C. Wainwright price target on SRPT
Every H.C. Wainwright rating on SRPT
- Jul 29, 2025
- Jun 16, 2025
- Apr 2, 2025
- Nov 25, 2024
How other firms rate SRPT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Deutsche Bank | Hold | $18 | Nov 10, 2026 |
| Wolfe Research | Outperform | $27 | Jul 9, 2026 |
| Barclays | Equal Weight | $20 | Jan 28, 2026 |
| Wedbush | Outperform | $32 | Dec 9, 2025 |
Questions about H.C. Wainwright and SRPT
- What is H.C. Wainwright's price target for SRPT?
- H.C. Wainwright's latest stated price target for Sarepta Therapeutics Inc. (SRPT) is $5, from its action on Jul 29, 2025.
- What is H.C. Wainwright's rating on SRPT?
- H.C. Wainwright rates SRPT Sell, a bearish rating, as of Jul 29, 2025.
- When did H.C. Wainwright last change its view on SRPT?
- On Jul 29, 2025, H.C. Wainwright reiterates Sell, price target $5.
- How does H.C. Wainwright's SRPT target compare with other analysts?
- Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50.
More SRPT rating histories
- Deutsche Bank4
- Barclays4
- BMO Capital Markets3
- Oppenheimer4
- Citigroup4
- Needham5
- Morgan Stanley6
- Cantor Fitzgerald4
- RBC Capital Markets5
- Credit Suisse3
All H.C. Wainwright ratingsSRPT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.